secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lexaria Bioscience Corp. (LEXX)
CIK:        0001348362
Form:       8-K
Filed at:   2023-03-03T23:59:59+00:00
Accession:  0001640334-23-000297
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexaria's DehydraTECH-CBD diabetes study shows weight loss, improved triglycerides and cholesterol in obese rats
--------------------------------------------------------------------------------

- 7% body weight loss maintained over 8 weeks in obese diabetic Zucker rats dosed with DehydraTECH-CBD.
- Triglyceride levels over 25% lower at 30 mg/Kg dose vs untreated obese rats (p=0.007).
- Lower dose (30 mg/Kg) improved HDL cholesterol without significant effect on LDL; higher dose increased both.
- Lower dose significantly improved locomotor activity (p<0.05) compared to untreated obese controls.
- Study DIAB-A22-1 conducted by third-party lab in Canada over 8 weeks; no serious health concerns observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423000297/0001640334-23-000297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348362/000164033423000297/lxrp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-23-000297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer